Free tool
FAERS Monitor: Ojemda
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217700 or its brand name (Ojemda, Tovorafenib). Reports on generic versions are filed under their own applications.
Reports
326
Serious
108
33% of reports
Hospitalization
41
Death reported
12
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use34
- disease progression28
- rash27
- fatigue23
- accidental underdose19
- hair colour changes18
- headache17
- melanocytic naevus15
- growth retardation12
- blood creatine phosphokinase increased11
- nausea11
- acne10
- dermatitis acneiform10
- intracranial tumour haemorrhage10
- photosensitivity reaction9
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 69 |
| 2025 | 179 |
| 2026 | 78 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,833 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intracranial tumour haemorrhageSignal | 10 | 1713.1 | 922.9 | 15,043 |
| growth retardationSignal | 12 | 264.1 | 151.4 | 2,876 |
| melanocytic naevusSignal | 15 | 221.5 | 135.0 | 3,066 |
| dermatitis acneiformSignal | 10 | 106.2 | 57.7 | 938 |
| hair colour changesSignal | 18 | 93.5 | 59.6 | 1,554 |
| accidental underdoseSignal | 19 | 85.3 | 55.1 | 1,498 |
| photosensitivity reactionSignal | 9 | 35.2 | 18.5 | 266 |
| blood creatine phosphokinase increasedSignal | 11 | 24.7 | 13.8 | 227 |
| disease progressionSignal | 28 | 15.3 | 10.7 | 361 |
| acneSignal | 10 | 8.5 | 4.6 | 59 |
| rashSignal | 27 | 4.0 | 2.8 | 59 |
| off label useSignal | 34 | 2.5 | 1.8 | 31 |
| fatigue | 23 | 1.9 | 1.3 | 9 |
| headache | 17 | 1.7 | 1.1 | 5 |
| nausea | 11 | 0.9 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.